JP2020028300A5 - - Google Patents

Download PDF

Info

Publication number
JP2020028300A5
JP2020028300A5 JP2019201128A JP2019201128A JP2020028300A5 JP 2020028300 A5 JP2020028300 A5 JP 2020028300A5 JP 2019201128 A JP2019201128 A JP 2019201128A JP 2019201128 A JP2019201128 A JP 2019201128A JP 2020028300 A5 JP2020028300 A5 JP 2020028300A5
Authority
JP
Japan
Prior art keywords
mutation
pik3ca
sequence
polynucleotide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019201128A
Other languages
English (en)
Japanese (ja)
Other versions
JP6694543B2 (ja
JP2020028300A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020028300A publication Critical patent/JP2020028300A/ja
Publication of JP2020028300A5 publication Critical patent/JP2020028300A5/ja
Application granted granted Critical
Publication of JP6694543B2 publication Critical patent/JP6694543B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2019201128A 2004-03-02 2019-11-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 Expired - Lifetime JP6694543B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02
US60/548,886 2004-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018090580A Division JP6695381B2 (ja) 2004-03-02 2018-05-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020038337A Division JP7169315B2 (ja) 2004-03-02 2020-03-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Publications (3)

Publication Number Publication Date
JP2020028300A JP2020028300A (ja) 2020-02-27
JP2020028300A5 true JP2020028300A5 (https=) 2020-04-16
JP6694543B2 JP6694543B2 (ja) 2020-05-13

Family

ID=35056655

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2007501815A Withdrawn JP2007530017A (ja) 2004-03-02 2005-02-18 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2012052427A Expired - Lifetime JP5336620B2 (ja) 2004-03-02 2012-03-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2013100073A Expired - Lifetime JP5894110B2 (ja) 2004-03-02 2013-05-10 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2015245769A Expired - Lifetime JP6250017B2 (ja) 2004-03-02 2015-12-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2017202265A Expired - Lifetime JP6395917B2 (ja) 2004-03-02 2017-10-19 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2018090580A Expired - Lifetime JP6695381B2 (ja) 2004-03-02 2018-05-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2019201128A Expired - Lifetime JP6694543B2 (ja) 2004-03-02 2019-11-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2020038337A Expired - Lifetime JP7169315B2 (ja) 2004-03-02 2020-03-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2020078786A Expired - Lifetime JP7001735B2 (ja) 2004-03-02 2020-04-28 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2022022542A Expired - Lifetime JP7304987B2 (ja) 2004-03-02 2022-02-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Family Applications Before (6)

Application Number Title Priority Date Filing Date
JP2007501815A Withdrawn JP2007530017A (ja) 2004-03-02 2005-02-18 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2012052427A Expired - Lifetime JP5336620B2 (ja) 2004-03-02 2012-03-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2013100073A Expired - Lifetime JP5894110B2 (ja) 2004-03-02 2013-05-10 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2015245769A Expired - Lifetime JP6250017B2 (ja) 2004-03-02 2015-12-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2017202265A Expired - Lifetime JP6395917B2 (ja) 2004-03-02 2017-10-19 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2018090580A Expired - Lifetime JP6695381B2 (ja) 2004-03-02 2018-05-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020038337A Expired - Lifetime JP7169315B2 (ja) 2004-03-02 2020-03-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2020078786A Expired - Lifetime JP7001735B2 (ja) 2004-03-02 2020-04-28 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2022022542A Expired - Lifetime JP7304987B2 (ja) 2004-03-02 2022-02-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Country Status (14)

Country Link
US (6) US8026053B2 (https=)
EP (5) EP2497836B1 (https=)
JP (10) JP2007530017A (https=)
AU (2) AU2005227148B2 (https=)
CA (1) CA2560696C (https=)
CY (1) CY1121975T1 (https=)
DK (3) DK3556866T3 (https=)
ES (5) ES2437590T3 (https=)
HU (1) HUE045690T2 (https=)
LT (1) LT3296407T (https=)
PL (2) PL3296407T3 (https=)
PT (3) PT1730303E (https=)
SI (2) SI3296407T1 (https=)
WO (1) WO2005091849A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530017A (ja) 2004-03-02 2007-11-01 ザ ジョンズ ホプキンス ユニバーシティ ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
KR20100105648A (ko) 2007-12-03 2010-09-29 엔즌 파마슈티칼스, 인코포레이티드 Ｐｉｋ３ｃａ 발현 조절용 ｒｎａ 길항제 화합물
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
EP2553463B1 (en) 2010-03-26 2017-05-03 Hongzhi Zou Methods and materials for detecting colorectal neoplasm
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法
WO2012106175A1 (en) 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
ES2986436T3 (es) 2011-04-15 2024-11-11 Univ Johns Hopkins Sistema de secuenciación segura
US20140298493A1 (en) * 2011-07-28 2014-10-02 Somasekar Seshagiri PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
ES2886507T5 (es) 2012-10-29 2024-11-15 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
EP2971075B1 (en) * 2013-03-13 2018-08-15 Roche Diagnostics GmbH Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
EP3027654B1 (en) * 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
CN120700143A (zh) 2014-03-31 2025-09-26 梅奥医学教育和研究基金会 检测结直肠赘生物
DK3198026T3 (da) * 2014-08-07 2020-01-20 Pharmassist Ltd Fremgangsmåde til bestemmelse af pik3ca-mutationsstatus i en prøve
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
US10689710B2 (en) * 2015-05-27 2020-06-23 Quest Diagnostics Investments Incorporated Methods for screening solid tumors for mutations
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
CN114574585A (zh) 2015-08-31 2022-06-03 梅约医药教育及研究基金会 检测胃肿瘤
RU2018123524A (ru) 2015-12-03 2020-01-09 Новартис Аг Фармацевтическая диагностика
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
JP7481804B2 (ja) 2016-04-14 2024-05-13 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 高度膵異形成の検出
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
JP7356349B2 (ja) 2017-02-28 2023-10-04 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 前立腺癌検出
JP7224645B2 (ja) * 2017-03-30 2023-02-20 国立大学法人 東京大学 異なる複数の目的遺伝子の評価方法
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
JP7067896B2 (ja) 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体
JP7277460B2 (ja) 2017-11-30 2023-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 乳癌の検出
EP4103748A4 (en) 2020-02-14 2024-03-13 The Johns Hopkins University METHOD AND MATERIALS FOR ASSESSING NUCLEIC ACIDS
CN111363827A (zh) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 用于检测pik3ca基因突变的引物组及其应用方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN116219015A (zh) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
ATE388226T1 (de) * 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
WO2001055301A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
JP2005533604A (ja) 2002-07-25 2005-11-10 アバンテック バスキュラー コーポレーション 治療薬を送達する装置とこれに関する方法
AU2004228668B2 (en) * 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
JP2007530017A (ja) 2004-03-02 2007-11-01 ザ ジョンズ ホプキンス ユニバーシティ ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Similar Documents

Publication Publication Date Title
JP2020028300A5 (https=)
Carvalhais et al. Molecular diagnostics of banana fusarium wilt targeting secreted-in-xylem genes
JP2016500110A5 (https=)
JP2016513094A5 (https=)
JP2020519851A5 (https=)
EA202092900A3 (ru) Мутационный анализ днк в плазме для детектирования рака
JP2013066474A5 (https=)
JP2022533033A5 (https=)
JP2015523569A5 (https=)
Cha et al. Analysis of transcriptional profiles to discover biomarker candidates in Mycobacterium avium subsp. paratuberculosis-infected macrophages, RAW 264.7
Vinayanuwattikun et al. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer
CN105200122B (zh) 小麦条锈菌的定量检测试剂盒及其应用
JP2019529959A5 (https=)
WO2015121737A3 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
CN108893533B (zh) 用于预测或辅助预测肺部辐射后患放射性肺炎风险的试剂盒
BR112021023247A2 (pt) Métodos de diagnóstico e tratamento do câncer cervical
NZ584656A (en) Mitochondrial dna deletion between about residues 12317-16254 for use in the detection of cancer
RU2565554C2 (ru) СПОСОБ ДИФФЕРЕНЦИАЦИИ БИОВАРОВ И ГЕНОВАРИАНТОВ ШТАММОВ Yersinia pestis ОСНОВНОГО ПОДВИДА С ПОМОЩЬЮ ПОЛИМЕРАЗНОЙ ЦЕПНОЙ РЕАКЦИИ
CN105713975A (zh) 一种快速检测–α2.4缺失型α地贫等位基因的试剂盒
JP6323829B2 (ja) コンブの原産国判別方法並びにプライマー及びプライマーを含むキット
JP2016123340A (ja) 膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤
Rock et al. Development and validation of a gene expression signature to distinguish malignant melanoma from benign nevi
DE60313366D1 (de) Nukleinsäuresonden und Verfahren zum Nachweis einer Zielnukleinsäuresequenz mit zwei oder mehr cis-Nukleinsäurebereichen
Chapusot 34P Recommendations for EGFR mutation testing with a fast and fully automated sample-to-result system: How to optimize DNA input instead of using lung cancer tissue?
DE60329224D1 (de) Verfahren zur Bestimmung von zirkulierender DNS in Plasma und zum Nachweis von Krebs